Date: 2014-01-17
Type of information: Collaboration agreement
Compound:
Company: Axxam (Italy) Cellectis bioresearch (France)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 17, 2014, Axxam, a provider of discovery services including assay development for high-throughput screening, and Cellectis bioresearch, a cell engineering company genome providing customization tools and services, have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies. Under the joint offering, clients will be provided with a one-stop-shop approach for the generation of cell-based assays through genomic engineering. Genes of interest will be modified using Cellectis bioresearch’s proprietary genome engineering technologies, after which functional cellular assays will be developed using Axxam’s expertise and technologies for cell line generation. Both the required gene modification and the resulting functionality change will be experimentally demonstrated. Finally, validated assays for screening and profiling experiments will be provided to the client. With the currently available genome engineering technologies virtually any gene, at any position, in any cell type can be addressed for a wide range of applications such as knock-in insertions, knock-out deletions, reporter cell line generations and others.
Financial terms:
Latest news:
